US007718629B2

(12) **United States Patent**
Bumcrot et al.

(10) **Patent No.: US 7,718,629 B2**
(45) **Date of Patent: May 18, 2010**

(54) **COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 GENE**

(75) Inventors: **David Bumcrot**, Belmont, MA (US); **Pamela Tan**, Kulmbach (DE); **Hans-Peter Vornlocher**, Bayreuth (DE); **Anke Geick**, Bayreuth (DE)

(73) Assignee: **Alnylam Pharmaceuticals, Inc.**, Cambridge, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 8 days.

(21) Appl. No.: **11/694,215**

(22) Filed: **Mar. 30, 2007**

(65) **Prior Publication Data**

US 2007/0281899 A1 Dec. 6, 2007

Related U.S. Application Data

(60) Provisional application No. 60/787,762, filed on Mar. 31, 2006, provisional application No. 60/870,259, filed on Dec. 15, 2006.

(51) **Int. Cl.**

A61K 31/70	(2006.01)
A01N 43/04	(2006.01)
C07H 21/02	(2006.01)
C07H 21/04	(2006.01)

(52) **U.S. Cl.** **514/44**; 536/23.1; 536/24.3; 536/24.33; 536/24.5

(58) **Field of Classification Search** 536/23.1, 536/24.3, 24.33, 24.5; 435/6, 91.1, 325, 435/375; 514/44

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,426,330	A	1/1984	Sears
4,534,899	A	8/1985	Sears
4,837,028	A	6/1989	Allen
4,868,116	A	9/1989	Morgan et al.
4,980,286	A	12/1990	Morgan et al.
5,013,556	A	5/1991	Woodle et al.
5,139,941	A	8/1992	Muzyczka et al.
5,213,804	A	5/1993	Martin et al.
5,225,212	A	7/1993	Martin et al.
5,252,479	A	10/1993	Srivastava
5,264,221	A	11/1993	Tagawa et al.
5,328,470	A	7/1994	Nabel et al.
5,334,711	A	8/1994	Sproat et al.
5,356,633	A	10/1994	Woodle et al.
5,540,935	A	7/1996	Miyazaki et al.
5,543,152	A	8/1996	Webb et al.
5,556,948	A	9/1996	Tagawa et al.
5,595,760	A	1/1997	Cherif-Cheikh
5,627,053	A	5/1997	Usman et al.
5,665,710	A	9/1997	Rahman et al.
5,672,659	A	9/1997	Shalaby et al.
5,705,188	A	1/1998	Junichi et al.
5,716,824	A	2/1998	Beigelman et al.
5,854,038	A	12/1998	Sullenger et al.
5,902,880	A	5/1999	Thompson
6,054,299	A	4/2000	Conrad
6,146,886	A	11/2000	Thompson
6,150,092	A	11/2000	Uchida et al.
6,395,713	B1	5/2002	Beigelman et al.
2003/0203844	A1	10/2003	Delfani et al.
2004/0018176	A1	1/2004	Tolentino et al.
2004/0180847	A1	9/2004	Dobie et al.
2004/0209832	A1	10/2004	McSwiggen et al.
2005/0255487	A1	11/2005	Khvorova et al.
2007/0031844	A1	2/2007	Khvorova et al.

FOREIGN PATENT DOCUMENTS

DE	101 00 586	4/2002
EP	0 445 131	10/1989
EP	0 496 813	10/1990
WO	WO 88/04924	7/1988
WO	WO 89/02468	3/1989
WO	WO 89/05345	6/1989
WO	WO 89/07136	8/1989
WO	WO 90/04384	5/1990
WO	WO 91/05545	5/1991
WO	WO 92/07065	4/1992
WO	WO 92/07573	5/1992

(Continued)

OTHER PUBLICATIONS

Weil et al. Targeting the Kinesin Eg5 to Monitor siRNA Transfection in Mammalian Cells. (BioTechniques, 2002 vol. 33. No. 6(1244-1248).*

(Continued)

Primary Examiner—Sean McGarry
Assistant Examiner—Terra Cotta Gibbs
(74) *Attorney, Agent, or Firm*—Fenwick & West LLP

(57) **ABSTRACT**

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Eg5 gene (Eg5 gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the Eg5 gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by Eg5 expression and the expression of the Eg5 gene using the pharmaceutical composition; and methods for inhibiting the expression of the Eg5 gene in a cell.

33 Claims, No Drawings